In addition, dovitinib reduced STAT3 activation to induce cell apoptosis in two sorafenib-resistant cell lines, and sorafenib-resistant cells showed significant activation of STAT3, indicating that STAT3 may be a useful target to overcome drug resistance in HCC (54). This evidence concerns the gene STAT3 and hepatocellular carcinoma.